Fig. 5.
Fig. 5. Killing of CLL cells by T-cell lines generated against native and heteroclitic peptides. / (A) Killing of CLL cells with a T-cell line generated against native or heteroclitic peptide with rearranged Ig gene containing the sequence for the FR9, FR16, FR17, FR18, FR23, FR26, and CDR17 peptides. Results shown are at an effector-to-target ratio of 30:1 and are the mean ± SD values from experiments done in triplicate with samples from 3 different donors. (B) Killing of CLL cells by a T-cell line generated from autologous T cells against FR17 native and heteroclitic peptides at the effector-to-target ratios shown. (C) Killing of CLL cells occurs in an MHC-restricted manner and is inhibited by addition of anti–HLA-A2 mAb at a concentration of 5 μg/mL.

Killing of CLL cells by T-cell lines generated against native and heteroclitic peptides.

(A) Killing of CLL cells with a T-cell line generated against native or heteroclitic peptide with rearranged Ig gene containing the sequence for the FR9, FR16, FR17, FR18, FR23, FR26, and CDR17 peptides. Results shown are at an effector-to-target ratio of 30:1 and are the mean ± SD values from experiments done in triplicate with samples from 3 different donors. (B) Killing of CLL cells by a T-cell line generated from autologous T cells against FR17 native and heteroclitic peptides at the effector-to-target ratios shown. (C) Killing of CLL cells occurs in an MHC-restricted manner and is inhibited by addition of anti–HLA-A2 mAb at a concentration of 5 μg/mL.

Close Modal

or Create an Account

Close Modal
Close Modal